Hepatocellular carcinoma in Australia’s Northern Territory: High incidence and poor outcome

Medical Journal of Australia

Volumn 201, Issue 8, 2014, Pages 470-474

  Parker, Christopher ^a   Tong, Steven Y C ^a   Dempsey, Karen ^b   Condon, John ^a   Sharma, Suresh K ^c   Chen, John W C ^d   Sievert, William ^e   Davis, Joshua S ^a  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b Department of Health and Families   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; AUSTRALIA; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; DISEASE SURVEILLANCE; ECHOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SEROPREVALENCE; AGE DISTRIBUTION; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGY; FOLLOW UP; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TIME; TRENDS;

AGE DISTRIBUTION; AGED; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NORTHERN TERRITORY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84919336910     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.11117     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Liver cancer. http://globocan.iarc.fr/Pages/fact_sheets_ cancer.aspx (accessed Jan 2014).
3. Australian Institute of Health and Welfare. Cancer in Australia 2010: an overview. Canberra: AIHW, 2010. (AIHW Cat. No. CAN 56; Cancer Series No. 60.) https://www.aihw.gov.au/ publication-detail/?id=6442472459 (accessed Feb 2014).
4. MacLachlan JH, Cowie BC. Liver cancer is the fastest increasing cause of cancer death in Australians. Med J Aust 2012; 197: 492-493.
5. Wan X, Mathews JD. Primary hepatocellular carcinoma in Aboriginal Australians. Aust J Public Health 1994; 18: 286-290.
6. Condon JR, Barnes T, Cunningham J, Armstrong BK. Long-term trends in cancer mortality for Indigenous Australians in the Northern Territory. Med J Aust 2004; 180: 504-507.
7. Liu B, Guthridge S, Li SQ, et al. The end of the Australia antigen? An ecological study of the impact of universal newborn hepatitis B vaccination two decades on. Vaccine 2012; 30: 7309-7314.
8. Carroll E, Page W, Davis JS. Screening for hepatitis B in East Arnhem Land: a high prevalence of chronic infection despite incomplete screening. Intern Med J 2010; 40: 784-787.
9. Dent E, Selvey CE, Bell A, et al. Incomplete protection against hepatitis B among remote Aboriginal adolescents despite full vaccination in infancy. Commun Dis Intell Q Rep 2010; 34: 435-439.
10. Wood N, Backhouse J, Gidding HF, et al. Estimates of chronic hepatitis B virus infection in the Northern Territory. Commun Dis Intell Q Rep 2005; 29: 289-290.
11. Graham S, Guy RJ, Cowie B, et al. Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and metaanalysis. BMC Infect Dis 2013; 13: 403.
12. MacLachlan JH, Allard N, Towell V, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust N Z J Public Health 2013; 37: 416-422.
13. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
14. Chondur R, Guthridge S. Population data in the Northern Territory. Darwin: Department of Health and Community Services, 2006. http:// digitallibrary.health.nt.gov.au/prodjspui/ bitstream/10137/113/1/population_info_paper_ formatted_aug06.pdf (accessed Jan 2014).
15. Australian Bureau of Statistics. Australian demographic statistics, September quarter 2002. Canberra: ABS, 2003. (ABS Cat. No. 3101.0.) http://www.abs.gov.au/AUSSTATS/ subscriber.nsf/log?openagent&31010_sep%20 2002.pdf&3101.0&Publication&104DE27A79 8E5A37CA256CEE008139E4&24&Sep%20 2002&20.03.2003&Previous (accessed Feb 2014).
16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
17. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
18. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
19. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
20. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54: 801-807.
21. Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013; 34: 1800-1805.
22. Robotin MC, Kansil M, Howard K, et al. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol 2009; 50: 990-998.